Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.66 |
| ▸ | C1R | P00736 | 3/20 | 0.60 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12897207 | 0.85 | HSD17B10 (0.59) | ELANEC1RPBRM1HSD17B10NPC1 | |
| SCHEMBL8215031 | 0.83 | ELANE (0.66) | ELANEC1RHSD17B10NPC1TP53 | |
| SCHEMBL6246926 | 0.80 | ELANE (0.73) | ELANEC1RPBRM1NPC1RAB9A | |
| SCHEMBL9984780 | 0.80 | ELANE (1.00) | ELANEC1RPBRM1 | |
| SCHEMBL8203003 | 0.78 | ELANE (0.63) | ELANEC1RHSD17B10NPC1TP53 | |
| SCHEMBL8210844 | 0.77 | ELANE (0.67) | ELANEC1RPBRM1 | |
| SCHEMBL12927377 | 0.76 | KDM4E (0.45) | ELANEHSD17B10NPC1TP53RAB9A | |
| SCHEMBL9984683 | 0.75 | ELANE (1.00) | ELANEC1RPBRM1NPC1RAB9A | |
| SCHEMBL4190607 | 0.75 | ELANE (0.79) | ELANEC1RPBRM1L3MBTL1 | |
| SCHEMBL9985824 | 0.75 | ELANE (1.00) | ELANEC1RPBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879846-B2 | e.g. 2-(2-Imidazol-1-yl-pyridin-3-yl)-5-methyl-4H-benz[d][1,3]oxazin-4-one ; neutrophil elastase inhibitor; antiinflammatory agent, respiratory system disorders | Kyorin Pharmaceutical Co.., Ltd. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7879846-B2 | e.g. 2-(2-Imidazol-1-yl-pyridin-3-yl)-5-methyl-4H-benz[d][1,3]oxazin-4-one ; neutrophil elastase inhibitor; antiinflammatory agent, respiratory system disorders | Kyorin Pharmaceutical Co.., Ltd. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20080161290-A1 | Serine hydrolase inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20080161290-A1 | Serine hydrolase inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161290-A1 | Serine hydrolase inhibitors | SERPINB1, ELANE, EPX | ELANE 2/4885C1R 1386/4885PBRM1 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.